Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


Doc advisory meets shut down

Posted 13 March 2020

More effects of COVID-19 are being felt across industry as advisory board meetings with top doctors become latest victim of the global outbreak. 

The advisory meetings are a staple of pharmaceutical company operations. In the last Medicines Australia (MA) reporting period, member companies outlaid at least $1.2 million to HCPs for advisory board or committee membership over six months. 

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Pharma face-slapped for success
Reputation is finding itself under threat again
Approvals Action
Low dose Symdeko ticked
Along with one generic drug
Special Report
March 2021 PBAC outcomes
Less than a quarter of major new listing requests recommended